Co-Diagnostics Inc (HAM:C970)

Q1 2025 Co-Diagnostics Inc Earnings Call Transcript

May 8, 2025 / 08:30 PM GMT

Release Date Price: €9.3 (+1.97%)

Transcript 10-Q8-K

Key Points

Positve

Co-Diagnostics Inc (CODX) is advancing its CoD PCR platform and associated test pipeline towards clinical evaluations, aiming to bring low-cost, rapid, and easy-to-use diagnostics to the market.
The company is supported by leading organizations like the Bill and Melinda Gates Foundation and the National Institute of Health's RAX tech program, enhancing its credibility and resources.
Co-Diagnostics Inc (CODX) has completed the design and extensive verification testing for its augmented Kodiak PCR COVID-19 test, showing confidence in its performance and stability.
The company is making significant progress on its 4plex respiratory panel and 8plex HPV panel, with plans to initiate clinical evaluations in the second half of the year.
Co-Diagnostics Inc (CODX) is expanding its manufacturing capabilities, including an oligonucleotide synthesis facility, to support future commercial launches and enhance operational efficiencies.

Negative

Total revenue for the first quarter of 2025 decreased significantly to $0.1 million compared to $0.5 million in the prior year's same period.
The company reported a net loss of $7.5 million for the first quarter of 2025, although this is an improvement from the $9.3 million loss in the prior year period.
The timeline for the resubmission of the COVID-19 test to the FDA is uncertain, as it depends on the prevalence of COVID-19 in the United States.
There are constraints related to the availability of samples for clinical trials, particularly for the COVID-19 test, which could delay the process.
The company is still in the process of seeking regulatory approvals and has not yet launched its new diagnostic solutions commercially, which could impact revenue generation in the near term.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CODX.OQ - Co-Diagnostics Inc
Q1 2025 Co-Diagnostics Inc Earnings Call
May 08, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by. My name is Kath and I will be your conference operator today. At this time, I would like to welcome everyone to the code diagnostics first quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question.

Simply press one again. I would now like to turn the call over to Andrew Benson, head of investor relations. Please go ahead.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.